Modality
Fusion Protein
MOA
PCSK9i
Target
EGFR
Pathway
Ferroptosis
DMDMigraine
Development Pipeline
Preclinical
~Apr 2016
→ ~Jul 2017
Phase 1
Oct 2017
→ Dec 2028
Phase 1Current
NCT05402668
1,536 pts·DMD
2023-06→2028-12·Recruiting
NCT08105941
2,571 pts·Migraine
2017-10→2026-01·Completed
4,107 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-01-142mo agoInterim· Migraine
2028-12-042.7y awayInterim· DMD
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1
Complet…
P1
Recruit…
Catalysts
Interim
2026-01-14 · 2mo ago
Migraine
Interim
2028-12-04 · 2.7y away
DMD
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05402668 | Phase 1 | DMD | Recruiting | 1536 | EASI-75 |
| NCT08105941 | Phase 1 | Migraine | Completed | 2571 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| INC-1261 | Incyte | Phase 1/2 | PRMT5 | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR | |
| Mavutuximab | Hansoh Pharma | Phase 2/3 | PI3Kα |